Cdc34 Antibodies

Santa Cruz Biotechnology features a diverse variety of Cdc34 monoclonal antibodies for research in cell cycle regulation and ubiquitin-mediated protein degradation. Cdc34 Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Cdc34, a key E2 ubiquitin-conjugating enzyme, plays a crucial role in the ubiquitin-proteasome pathway, facilitating the degradation of proteins that regulate the cell cycle. The function of Cdc34 is vital for maintaining cellular homeostasis and ensuring proper cell division, making it an important target for studies related to cancer and other proliferative diseases. Understanding the mechanisms of Cdc34 can provide insights into therapeutic strategies for targeting aberrant cell cycle progression. Research focused on Cdc34 continues to reveal new aspects of cell cycle control and protein degradation pathways. Investigating Cdc34 function has significant implications for developing targeted therapies in cancer treatment. The comprehensive characterization of Cdc34's cellular functions helps advance our understanding of fundamental biological processes. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific knowledge of cell cycle regulation and protein degradation mechanisms.